Pfizer Inc. announced today that a Phase 3 study of INLYTA ® (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival (PFS), versus sorafenib, in treatment-naïve patients with advanced renal cell carcinoma (RCC). A preliminary review of the data showed that overall the median PFS for INLYTA exceeded the median PFS for sorafenib, but did not meet statistical significance. In a pre-specified subgroup of patients classified as good Performance Status (ECOG PS 0), the median PFS for INLYTA exceeded the median PFS for sorafenib. In another pre-specified subgroup of patients classified as intermediate Performance Status (ECOG PS 1), there was no difference between INLYTA and sorafenib. Adverse events for INLYTA were generally consistent with previous findings in INLYTA patients with advanced RCC who had been treated with a prior systemic therapy. These data will be further analyzed and presented at an upcoming medical congress. “We narrowly missed the primary endpoint in this trial,” said Dr. Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer's Oncology Business Unit. “We are analyzing the study findings to determine whether further evaluation of INLYTA in specific subpopulations of treatment-naïve patients with advanced RCC would be warranted.” AGILE 1051, a trial of more than 280 treatment-naïve patients with advanced RCC, was powered to show a 78 percent improvement in PFS benefit with INLYTA over sorafenib. The primary endpoint of the study was PFS. The secondary endpoints of the study included overall survival, response rate and safety. Pre-specified subgroups were also analyzed and included patients with either good Performance Status (ECOG PS 0) or intermediate Performance Status (ECOG PS 1). ECOG performance status is a standard measure used to assess functional status of patients and these were stratification factors at randomization. Earlier this year, INLYTA was approved for patients with previously treated advanced RCC in the U.S., EU, Japan, Switzerland, Canada, Korea, and Australia. In its registrational Phase 3 AXIS trial, INLYTA significantly extended PFS with a median PFS of 6.7 months as compared to 4.7 months for those treated with sorafenib. The differences in PFS observed in the subgroups in the AXIS trial favored INLYTA over sorafenib, including in the ECOG PS 0 and ECOG PS 1 subgroups.